This prospective, comparative study was approved by the Ethical Review Committee of Zhongshan Ophthalmic Center, and it adhered to the provisions of the Declaration of Helsinki for research involving human subjects. Written informed consent was obtained from all participants involved in the study. All subjects were from a Chinese Han population, and all participants were patients at the Zhongshan Ophthalmic Center.
The study included 23 eyes of 17 PACG patients with vision sufficient to allow fixation on the eye examination. All enrolled patients met the following strict criteria: (1) PACG diagnostic criteria met; (2) advanced or late stage of the disease; (3) uncontrolled IOP after standardized maximum antiglaucoma medications and trabeculectomy required to prevent progressive glaucomatous optic neuropathy; (4) no complications after surgery and IOP reduction after trabeculectomy higher than 25% compared to baseline and postoperative IOP no lower than 5 mm Hg; and (5) with or without mild cataract to allow for clear EDI-OCT pictures. Patients with any of the following criteria were excluded: primary open-angle glaucoma (POAG), secondary glaucoma (such as lens subluxation, uveitis, iris neovascularization, trauma, tumor, or any obvious cataract leading to an intumescent lens), diabetes or systemic hypertension, a history of intraocular surgery, or inability to tolerate gonioscopy or an ultrasonographic biomicroscopy examination. Other exclusion criteria included high myopia or hyperopia (greater than +6 or −6 diopters [D] of the spherical equivalent refractive error), any retinal or retinal pigment epithelium detachment, any retinal abnormalities (such as choroidal neovascularization, asymptomatic pigment epithelial detachment, or whitish myopic atrophy), clinically relevant opacities of the optic media, and low-quality images due to unstable fixation or a severe cataract.
In this study, PACG was diagnosed in eyes with narrow angles (eyes in which the posterior trabecular meshwork was not seen for at least 180° on indentation gonioscopy in the primary position) with peripheral anterior synechiae and/or raised IOP (defined as IOP > 21 mm Hg). Also included were eyes with glaucomatous optic neuropathy (vertical cup-disc asymmetry between fellow eyes of ≥0.2, a cup-to-disc ratio of ≥0.6, and neuroretinal rim narrowing, notches, or localized pallor), and with compatible visual field loss on static automated perimetry Swedish Interactive Threshold Algorithm (SITA) standard with a 24-2 test pattern [Humphrey visual field analyzer II; Carl Zeiss Meditec, Dublin, CA, USA]). This was defined as a glaucoma hemifield test outside normal limits, having an abnormal pattern and a P value SD of <5% in the normal population and fulfilling test reliability criteria (fixation losses < 20%, false positives < 15%, and/or false negatives < 15%).
All patients underwent standard trabeculectomy performed by one glaucoma surgery specialist (XZ). Seven days after trabeculectomy, patients without early complications including shallow or flat anterior chamber, hyphema, choroidal detachment, wound leakage, acute endophthalmitis, suprachoroidal hemorrhage, vitreous hemorrhage, cystoid macular edema, hypotony, or transient elevation of IOP and in whom postoperative IOP was reduced to the range between 5 mm Hg and 21 mm Hg without the need of glaucoma medication were enrolled. Before surgery and 7 days after the surgery, the patients underwent an EDI-OCT examination. To limit any potential change in choroidal structure by antiglaucoma eye drops, no medications (especially pilocarpine to constrict the pupil) were administered to the eyes that underwent the EDI-OCT examination. The adjunctive antiglaucoma medication therapy for the PACG eyes before surgery included topical β-blocker (timolol 0.5%) twice daily and/or brimonidine (Azopt; Alcon Laboratories, Elkridge, MD, USA), and/or topical α-2 agonists (Alphagan; Allergan, Inc., Irvine, CA, USA); and/or prostaglandin analog, once daily (latanoprost [Xalatan]; Pfizer, Inc., NY, USA); oral acetazolamide, 250 mg three times daily; oral isosorbide, 50 g twice daily; and intravenous mannitol 20%, at 1 to 2 g/kg of body weight if necessary. The number of medications was counted.